RT Journal Article
SR Electronic
T1 Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 10
DO 10.1186/s40425-015-0054-4
VO 3
IS 1
A1 Cecchini, Michael
A1 Sznol, Mario
A1 Seropian, Stuart
YR 2015
UL http://jitc.bmj.com/content/3/1/10.abstract
AB Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.Abbreviations:GVHDGraft versus host diseaseIL-2Interleukin-2CTLA-4Cytotoxic T-lymphocyte associated proteinPD-1Programmed cell deathPD-L1Programmed death-ligand 1ASCTAllogeneic stem cell transplantsCMLChronic Myeloid LeukemiaCTComputed TomographyGKRSGamma knife radiosurgery